Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 6/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.51 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24487769 | 0.91 | AHCY (0.63) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL19590291 | 0.83 | ADORA3 (0.58) | HIF1AADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL24377184 | 0.83 | ADORA3 (0.58) | HIF1AADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL25389125 | 0.83 | ADORA3 (0.58) | HIF1AADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL29973013 | 0.83 | ADORA3 (0.58) | HIF1AADORA3ADORA2BADORA2AADORA1 | |
| SCHEMBL29611067 | 0.82 | ADK (0.48) | — | |
| SCHEMBL24313824 | 0.82 | ADK (0.48) | — | |
| SCHEMBL12300947 | 0.81 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL26554199 | 0.81 | AHCY (0.68) | AHCYHIF1ATMEM97SIGMAR1ADORA3 | |
| SCHEMBL21384830 | 0.81 | NT5E (0.49) | AHCYADORA3ADORA2BADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885 |
| US-11549110-B2 | Modified short interfering nucleic acid (siNA) molecules and uses thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885 |
| US-20220177888-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | AHCY 3101/4885HIF1A 1573/4885TMEM97 1392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.